0001415889-24-011058.txt : 20240417 0001415889-24-011058.hdr.sgml : 20240417 20240417192245 ACCESSION NUMBER: 0001415889-24-011058 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240416 FILED AS OF DATE: 20240417 DATE AS OF CHANGE: 20240417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LaBarre Michael J. CENTRAL INDEX KEY: 0001507174 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32335 FILM NUMBER: 24852458 MAIL ADDRESS: STREET 1: 11388 SORRENTO VALLEY ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001159036 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 880488686 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12390 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 794-8889 MAIL ADDRESS: STREET 1: 12390 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC DATE OF NAME CHANGE: 20040312 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC DATE OF NAME CHANGE: 20010912 4 1 form4-04172024_110437.xml X0508 4 2024-04-16 0001159036 HALOZYME THERAPEUTICS, INC. HALO 0001507174 LaBarre Michael J. C/O HALOZYME THERAPEUTICS, INC. 12390 EL CAMINO REAL SAN DIEGO CA 92130 false true false false SVP, CHIEF TECHNICAL OFFICER 1 Common Stock 2024-04-16 4 M 0 10000 8.11 A 178176 D Common Stock 2024-04-16 4 S 0 10000 38.35 D 168176 D Common Stock 2024-04-17 4 M 0 10000 8.11 A 178176 D Common Stock 2024-04-17 4 S 0 10000 38.489 D 168176 D Option to Purchase Common Stock 8.11 2024-04-16 4 M 0 10000 0 D 2026-02-03 Common Stock 10000 51715 D Option to Purchase Common Stock 8.11 2024-04-17 4 M 0 10000 0 D 2026-02-03 Common Stock 10000 41715 D The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023. Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.275 to $38.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. /s/ James R. Oehler, Attorney-in-Fact 2024-04-17